CA-327
PD-L1/TIM3-expressing Cancers
Proof of PrincipleNot a priority
Key Facts
About Curis
Curis is a clinical-stage oncology company dedicated to developing novel therapies that slow or prevent cancer progression. Its lead asset, Emavusertib, is an oral IRAK4 inhibitor in clinical trials for IRAK4-driven leukemias and lymphomas. The company also benefits from a collaboration with Roche/Genentech on the commercialized drug Erivedge for advanced basal cell carcinoma, providing non-dilutive funding. Curis is strategically focused on hematologic malignancies and immune checkpoint modulation.
View full company profile